Company Number: 14281449

Analysis Date: 2025-07-29 20:25 UTC

Financial Health Assessment for PHARMALOCUM1 LTD

---

1. Financial Health Score: C

Explanation:
PHARMALOCUM1 LTD shows signs of basic financial stability with positive net assets and current assets exceeding current liabilities, indicating the company can meet short-term obligations. However, a decline in net current assets and net assets compared to the previous year signals emerging caution. As a micro-entity with a small operational scale and minimal financial complexity, the financial health is adequate but vulnerable, warranting attention to maintain and improve liquidity and reserves.

---

2. Key Vital Signs

Metric	2024 (£)	2023 (£)	Interpretation
Current Assets	37,101	24,694	Healthy increase in liquid and receivable assets, supporting operational needs.
Current Liabilities	29,745	14,513	Significant increase in short-term liabilities; watch for potential liquidity strain.
Net Current Assets	7,356	10,181	Declined by ~28%, indicating tightening working capital — a "symptom of distress" in liquidity management.
Net Assets (Shareholders’ Funds)	7,356	10,181	Reduction in equity suggests retained earnings or reserves have been used or losses incurred.
Average Employees	2	2	Stable staffing level, consistent with small business size.

Interpretation:

• The rise in current assets is a "healthy pulse" showing potential growth in cash or receivables.
• However, the near doubling of current liabilities is a "warning sign" of increased short-term obligations that could strain cash flow.
• The reduced net current assets ("working capital") and net assets indicate a narrowing safety margin and potentially increased financial stress.
• The absence of an audit and the micro-entity status simplify reporting but limit detailed insight into underlying profitability or cash flow trends.

---

3. Diagnosis

PHARMALOCUM1 LTD presents as a small, early-stage business operating in the specialised dispensing chemist sector. Its financial "vital signs" show it remains solvent with positive net assets and working capital, but the recent increase in current liabilities and decrease in net assets suggest emerging liquidity pressure or operational challenges.

The company retains minimal but positive equity, implying no immediate threat to solvency but highlighting a "fragile health" state that requires close monitoring. The stable employee count suggests operational consistency rather than expansion or contraction.

Overall, the company resembles a patient with manageable but noticeable financial strain—no acute crisis but with clear symptoms that, if unattended, could worsen.

---

4. Recommendations

To improve financial wellness and avoid deterioration, PHARMALOCUM1 LTD should consider the following actions:

• Strengthen Cash Flow Management:
  Conduct a detailed review of cash inflows and outflows to ensure timely collection of receivables and control over payables. Avoid overextension on short-term liabilities.

• Reduce Short-Term Debt Burden:
  Explore options to renegotiate payment terms with creditors or convert some short-term liabilities into longer-term arrangements to ease liquidity pressure.

• Monitor Profitability Closely:
  Although profit and loss details are not publicly filed, internally track margins to ensure the business is generating sustainable earnings to rebuild reserves and equity.

• Build Financial Reserves:
  Aim to increase retained earnings or inject additional capital if necessary to improve net assets and provide a buffer against unexpected expenses.

• Maintain Compliance and Reporting:
  Continue timely submission of accounts and confirmation statements to avoid penalties and maintain good standing.

• Plan for Growth or Diversification:
  Consider strategies to increase turnover or diversify services to improve revenue stability and reduce dependency on limited income sources.

---